<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Peritoneal catheter exit-site and tunnel infections in peritoneal dialysis in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Peritoneal catheter exit-site and tunnel infections in peritoneal dialysis in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Peritoneal catheter exit-site and tunnel infections in peritoneal dialysis in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John M Burkart, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anthony Bleyer, MD, MS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas A Golper, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Wenliang Chen, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 25, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Peritoneal dialysis requires the placement and maintenance of a catheter that transverses the patient's abdominal wall and extends from the outer abdominal surface into the peritoneal cavity. The catheter exit site, tunnel, and peritoneum are prone to bacterial infection, which can cause morbidity and result in catheter removal.</p><p>This topic reviews the prevention, evaluation, and treatment of catheter-related infections including exit-site infections (ESIs) with or without tunnel infections. The microbiology and treatment of peritonitis and diagnosis of peritonitis in peritoneal dialysis patients are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1882.html" rel="external">"Microbiology and therapy of peritonitis in peritoneal dialysis"</a> and  <a class="medical medical_review" href="/z/d/html/1982.html" rel="external">"Fungal peritonitis in peritoneal dialysis"</a> and  <a class="medical medical_review" href="/z/d/html/1869.html" rel="external">"Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis"</a>.)</p><p class="headingAnchor" id="H12690226"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The catheter and exit site become colonized with bacteria soon after catheter placement. Bacteria secrete a biofilm, which encourages further bacterial growth and protects the colonizing organisms from antibodies, white blood cells, and antimicrobial agents.</p><p>Colonization predisposes to infection, which can occur following mild exit-site trauma. The infection may involve the exit site alone or the exit site and tunnel in which the catheter resides. A tunnel infection usually occurs only in the presence of an exit-site infection (ESI) [<a href="#rid1">1</a>].</p><p>Most exit site with or without tunnel infections are caused by gram-positive bacteria, usually <em>Staphylococcus</em> species [<a href="#rid2">2-7</a>]. Gram-negative organisms (<em>Pseudomonas aeruginosa</em> and <em>Escherichia coli</em>) cause the majority of the remainder [<a href="#rid2">2-7</a>].</p><p class="headingAnchor" id="H2401242325"><span class="h1">EPIDEMIOLOGY AND MICROBIOLOGY</span><span class="headingEndMark"> — </span>Exit-site infections (ESIs) have decreased since clinicians started using antimicrobial prophylaxis and other preventive measures [<a href="#rid2">2,8-10</a>]. Since daily topical antibiotic cream for infection prophylaxis became the standard of care, the reported rate of ESIs is approximately 12/100 patient-years [<a href="#rid11">11</a>]. (See <a class="local">'Prevention'</a> below.)</p><p>Risk factors associated with development of ESI include [<a href="#rid12">12-14</a>]:  </p><p class="bulletIndent1"><span class="glyph">●</span>Poor competency of exit-site care</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Catheter mobilization</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Catheter pulling-out injury </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mechanical compression of the catheter by a waist belt</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Swimming</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Presence of pets during exchanges</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Compression of the exit site by a peritoneal dialysis catheter bag (used in some countries) </p><p></p><p>Demographic factors such as age, sex, and race, and clinical factors such as diabetes or insulin dependence are not predictive of ESI [<a href="#rid6">6,15</a>]. </p><p>The causative agents have also changed with routine antibiotic prophylaxis. Although most infections are still caused by gram-positive organisms, the percentage caused by <em>Staphylococcus aureus</em> appears to have decreased with relative increases in other gram-positive organisms and gram-negative organisms [<a href="#rid2">2-7</a>]. In one study in which prophylactic topical <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> was used at the exit site, ESI was caused by <em>S. aureus</em> in 33 percent, other gram-positive organisms in 27 percent, and gram-negative organisms in 7 percent [<a href="#rid6">6</a>]. A sterile culture was obtained in 13 percent.</p><p>In addition, several studies have reported infection caused by uncommon organisms such as atypical mycobacteria, non-diphtheria <em>Corynebacteria</em>, and <em>Burkholderia cepacia</em> [<a href="#rid4">4-7,16</a>].</p><p>The relative proportion of fungal infections has increased with prophylactic antibiotics, although the frequency has not, which reflects the overall decrease in bacterial infections [<a href="#rid3">3,11</a>]. In the study cited above in which prophylactic topical <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> was used at the exit site, 20 percent of ESIs were caused by yeast [<a href="#rid6">6</a>].</p><p>The selection of the topical antimicrobial agent used for prophylaxis may alter the epidemiology of causative organisms. In a trial comparing <a class="drug drug_general" data-topicid="9668" href="/z/d/drug information/9668.html" rel="external">mupirocin</a> and <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> prophylaxis, 9 of 15 infections in the gentamicin group were from gram-positive organisms, and only one was from a gram-negative organism, whereas, in the mupirocin group, 17 of 29 were from gram-positive organisms and 9 of 29 were from gram-negative organisms [<a href="#rid6">6</a>]. In another study of 147 patients on peritoneal dialysis who received mupirocin prophylaxis for seven years, 11 percent of patients were <em>S. aureus</em> carriers, and 25 percent of these (representing 2.7 percent of the patient population) had mupirocin-resistant <em>S. aureus</em> [<a href="#rid17">17</a>]. </p><p class="headingAnchor" id="H2"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>The risk of exit-site and tunnel infection is decreased by preventive measures instituted prior to and immediately after catheter placement, as well as throughout the life of the catheter [<a href="#rid18">18</a>]. The following measures are largely consistent with the International Society for Peritoneal Dialysis (ISPD) published guidelines [<a href="#rid1">1,19</a>].</p><p class="headingAnchor" id="H4035905496"><span class="h2">Prior to catheter placement</span><span class="headingEndMark"> — </span>We administer systemic antibiotics immediately prior to surgery. The 2017 Kidney Disease: Improving Global Outcomes (KDIGO) and ISPD guidelines recommend screening and treating patients for <em>S. aureus</em> nasal carriage prior to peritoneal dialysis catheter insertion. However, we do not routinely test for <em>S. aureus</em> carriage because patient adherence to treatment of it is often suboptimal and because routine exit-site care includes the application of either <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> or <a class="drug drug_general" data-topicid="9668" href="/z/d/drug information/9668.html" rel="external">mupirocin</a> cream, which treat <em>S. aureus</em> [<a href="#rid1">1,20</a>]. Specific recommendations for systemic antibiotics are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1885.html" rel="external">"Placement of the peritoneal dialysis catheter"</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Immediately after surgery</span><span class="headingEndMark"> — </span>After placement of the catheter, the incision should be covered and the dressing left undisturbed for five to seven days. Any dressing changes required during this time should be done by a peritoneal dialysis nurse rather than the patient. The site should be kept dry, which precludes taking showers for at least three weeks [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Maintenance preventive care</span><span class="headingEndMark"> — </span>Routine maintenance measures to prevent infection include daily or every-other-day washing of the exit site and topical antimicrobial agents.</p><p class="headingAnchor" id="H71400278"><span class="h3">Washing and general care of the exit site</span><span class="headingEndMark"> — </span>Once the exit site is healed, it should be washed daily or every other day with antibacterial soap or an antiseptic. <a class="drug drug_general" data-topicid="9801" href="/z/d/drug information/9801.html" rel="external">Povidone iodine</a> solution (10%) and <a class="drug drug_general" data-topicid="9244" href="/z/d/drug information/9244.html" rel="external">chlorhexidine</a> solution (0.05 to 2%) have been shown to reduce the incidence of exit-site infection (ESI) compared with soap and water [<a href="#rid1">1,22,23</a>]. Hydrogen peroxide should not be used, since it tends to dry out the site and may be toxic to the normal granulation tissue.</p><p>When cleaning the exit site, crusts, if present, should not be forcibly removed. The exit should be dabbed dry after cleaning using a clean cloth or towel. We, and most other nephrologists, use a nonocclusive dressing (such as gauze) to cover the exit site, although one study suggests that a dressing may not be necessary [<a href="#rid24">24</a>].</p><p>We suggest that patients immobilize the catheter with tape to prevent accidental injury to the exit site, although there are no data that specifically support this practice [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H6"><span class="h3">Antimicrobial prophylaxis</span></p><p class="headingAnchor" id="H3698335753"><span class="h4">Daily topical antibiotics at exit site</span><span class="headingEndMark"> — </span>We prescribe a daily topical antimicrobial agent in addition to measures defined above [<a href="#rid1">1</a>]. (See <a class="local">'Washing and general care of the exit site'</a> above.)</p><p>Topical antibiotics decrease the risk of ESIs and peritonitis [<a href="#rid8">8,25-31</a>]. We suggest daily application of a topical antibiotic. Daily, compared with less frequent, application of topical antibiotics was associated with fewer ESIs and a lower level of antimicrobial resistance [<a href="#rid17">17,32-34</a>].</p><p>Two commonly used topical antibiotics are <a class="drug drug_general" data-topicid="9668" href="/z/d/drug information/9668.html" rel="external">mupirocin</a> and <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a>. Some experts prefer mupirocin while others use 0.1 percent topical gentamicin sulfate. Some peritoneal dialysis centers alternate between mupirocin and gentamicin by the month. Each approach is reasonable. Gentamicin is as effective as mupirocin against <em>S. aureus </em>and other gram-positive organisms and may be more effective against gram-negative organisms [<a href="#rid6">6,35-37</a>]. Gentamicin is generally less expensive than mupirocin.</p><p>Many other topical and oral antimicrobial agents, including Medihoney, have been studied but are generally considered experimental or unproven [<a href="#rid7">7,30,38-49</a>].</p><p class="headingAnchor" id="H2059360858"><span class="h4">Topical nasal antibiotics</span><span class="headingEndMark"> — </span>We do not use nasal antimicrobial agents for maintenance prophylaxis. Application of nasal antimicrobial agents is uncomfortable and of limited clinical benefit. In one trial of 267 patients, nasal application of <a class="drug drug_general" data-topicid="9668" href="/z/d/drug information/9668.html" rel="external">mupirocin</a> was associated with reduced incidence of ESI due to <em>S. aureus</em> (14 versus 44 infections over 18 months); however, the rates of peritonitis and all ESI were similar (33 per 1390 versus 55 per 1236 patient-months) [<a href="#rid20">20,50,51</a>].</p><p class="headingAnchor" id="H1385985289"><span class="h4">Oral antibiotics following catheter trauma</span><span class="headingEndMark"> — </span>We administer systemic oral antibiotics to all patients who report trauma to their exit site, although there are no data that specifically support this approach.</p><p>We give <a class="drug drug_general" data-topicid="9231" href="/z/d/drug information/9231.html" rel="external">cephalexin</a> for three days  (<a class="graphic graphic_table graphicRef67277" href="/z/d/graphic/67277.html" rel="external">table 1</a>). If the patient is allergic to cephalosporins, we give <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a> for three days  (<a class="graphic graphic_table graphicRef67277" href="/z/d/graphic/67277.html" rel="external">table 1</a>).</p><p>Granulomas may occasionally occur at the exit site. A trained nurse can apply <a class="drug drug_general" data-topicid="9888" href="/z/d/drug information/9888.html" rel="external">silver nitrate</a> to the granuloma on one occasion for cauterization. Another option is for the patient to apply <a class="drug drug_general" data-topicid="9244" href="/z/d/drug information/9244.html" rel="external">chlorhexidine</a> daily. In a randomized trial of 44 patients with exit-site granulomas, rates of healing were similar between chlorhexidine and silver nitrate (94 versus 100 percent, respectively) [<a href="#rid52">52</a>]. There was less pain associated with chlorhexidine application. </p><p class="headingAnchor" id="H4195155684"><span class="h3">Environment and lifestyle</span><span class="headingEndMark"> — </span>A clean environment and certain lifestyle changes may help reduce the rate of exit-site and tunnel infections, as suggested by observational data looking at environmental exposures [<a href="#rid53">53,54</a>].</p><p>Peritoneal dialysis patients are generally discouraged from taking baths, using hot tubs, or swimming in rivers, lakes, or the ocean. Swimming in swimming pools and salt water bodies may be safer, but not completely without risk of ESI and peritonitis [<a href="#rid13">13</a>]. In a cross-sectional survey of 39 Australian peritoneal dialysis units where swimming among patients was near-universal, seven episodes of ESI and two of peritonitis were attributed to swimming [<a href="#rid13">13</a>]. </p><p>However, when patients choose to swim or take a bath, we advise them to cover the catheter and exit site with an ostomy bag and to immobilize the catheter (ie, with tape). We instruct patients to do their daily exit-site care after swimming or bathing in a tub. </p><p>Pets in the house may increase the risk of infection, although zoonotic bacteria account for a low percentage of peritonitis episodes (0.03 to 0.54 percent) [<a href="#rid55">55</a>]. Although we generally do not actively discourage patients from having pets, we advise that pets remain out of the room when exchanges are performed.</p><p class="headingAnchor" id="H3931216887"><span class="h1">ROUTINE MONITORING</span><span class="headingEndMark"> — </span>The exit site should be examined daily by the patient and monthly by a clinician or the home unit medical staff in order to detect infection as early as possible. In addition, the exit site should be examined by a clinician whenever the patient detects a change in the appearance of the exit site.</p><p>Examination of the exit site begins with gross visual inspection. Some clinicians use a magnifying glass for closer observation, though we do not.<em> </em>The catheter tract should be milked to see if any drainage is present and observed for evidence of erythema overlying the tunnel, which is the part of the catheter between the two cuffs. Some clinicians routinely grade the exit during these monthly visits according to grading systems that have been developed for adult  (<a class="graphic graphic_table graphicRef61012 graphicRef73832" href="/z/d/graphic/61012.html" rel="external">table 2A-B</a>) [<a href="#rid56">56</a>] and pediatric patients  (<a class="graphic graphic_table graphicRef73622" href="/z/d/graphic/73622.html" rel="external">table 3</a>) [<a href="#rid57">57</a>].</p><p>We maintain a photographic record of the exit site (ie, using a mobile phone) so that accurate comparisons between visits are possible [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H3803938181"><span class="h1">CLINICAL PRESENTATION AND EVALUATION</span><span class="headingEndMark"> — </span>Any change from the patient's normal, healthy exit site may be a sign of a new exit-site infection (ESI)  (<a class="graphic graphic_table graphicRef61012 graphicRef73832" href="/z/d/graphic/61012.html" rel="external">table 2A-B</a>).</p><p class="headingAnchor" id="H1622417577"><span class="h2">Exit-site infection</span><span class="headingEndMark"> — </span>Typically, infection presents initially as increased crust formation and/or erythema surrounding the exit site and progresses to serous and purulent drainage arising from the exit site. Patients generally do not have fever or chills in the early stages of infection.</p><p>While any change from the patient's normal, healthy exit site may be a sign of a new ESI  (<a class="graphic graphic_table graphicRef61012 graphicRef73832" href="/z/d/graphic/61012.html" rel="external">table 2A-B</a>), changes limited to mild erythema, skin induration, or increased crust formation may alternatively reflect mild trauma involving the catheter or an allergic reaction [<a href="#rid57">57,58</a>].</p><p>We carefully examine the exit site and catheter tract. We milk the catheter tract to express drainage. Any drainage should be sent for Gram stain and culture to direct antibiotic therapy. Culture of the site is not helpful if drainage is not present, since, in the absence of discharge, positive cultures may just represent colonization. (See <a class="local">'Treatment'</a> below.)</p><p class="headingAnchor" id="H465714754"><span class="h2">Tunnel involvement</span><span class="headingEndMark"> — </span>Tunnel involvement manifests as erythema, edema, induration, or tenderness over the catheter pathway [<a href="#rid1">1</a>]. If untreated, infection may progress to abscess formation within the tunnel. Tunnel abscess is more likely with infections caused by <em>S. aureus</em> or <em>P. aeruginosa</em>.</p><p>We obtain an ultrasound of the catheter tract only if we suspect a tunnel abscess based on symptoms and physical examination (such as marked tenderness over the catheter pathway and drainage from the site after milking the tract) or if ESI is resistant to treatment. Ultrasound is effective in revealing fluid collections [<a href="#rid59">59</a>]. (See <a class="local">'Resistant infection'</a> below.)</p><p class="headingAnchor" id="H1145623061"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>We diagnose exit-site infection (ESI) if there is purulent discharge from the exit site, with or without erythema, or if there is severe acute erythema without purulent discharge that develops in the absence of acute trauma to the catheter [<a href="#rid1">1,60</a>].</p><p>We diagnose tunnel infection if there is erythema, edema, induration, or tenderness over the catheter pathway.</p><p>Even in the absence of drainage or severe erythema, any change in appearance of the exit raises the suspicion of infection, but we do not diagnose ESI, at least initially, among patients who present with only mild erythema, skin induration, or increased crust formation, since these changes alone may not represent an infection [<a href="#rid57">57,58</a>].</p><p>Erythema without infection is commonly observed following placement of the catheter or after mild trauma involving the catheter [<a href="#rid61">61</a>]. Skin erythema may also be a manifestation of an allergic reaction [<a href="#rid61">61</a>].</p><p>Patients with mild erythema, skin duration, or crust formation are closely followed for progression of local changes. We ask patients to examine the exit site daily and report any increase in erythema or crust formation or the development of discharge. The exit site should be evaluated by the clinician or home unit medical staff in one week. Serial photographs may be helpful to assess progression or improvement. It is important during this time to make sure that the patient is adhering to optimal catheter hygiene and preventive care. (See <a class="local">'Maintenance preventive care'</a> above.)</p><p class="headingAnchor" id="H15"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>We agree with the 2017 International Society for Peritoneal Dialysis (ISPD) guidelines that all exit-site infections (ESIs) with or without tunnel involvement should be treated with antibiotics [<a href="#rid1">1,19</a>]. The initial treatment of exit-site and tunnel infections is the same.</p><p>Untreated ESIs commonly lead to peritonitis [<a href="#rid62">62</a>]. In one retrospective study, over 30 percent of all cases of peritonitis associated with catheter infection were preceded by an exit site or tunnel infection [<a href="#rid62">62</a>]. Antibiotics are effective in treating ESIs.</p><p class="headingAnchor" id="H2674443996"><span class="h2">Empiric therapy</span><span class="headingEndMark"> — </span>We agree with the 2017 ISPD infections guidelines that empiric antibiotic therapy should be initiated based on Gram stain  (<a class="graphic graphic_algorithm graphicRef62413" href="/z/d/graphic/62413.html" rel="external">algorithm 1</a>) [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gram-positive organism </strong>– A first-generation oral cephalosporin (such as <a class="drug drug_general" data-topicid="9231" href="/z/d/drug information/9231.html" rel="external">cephalexin</a>) or a penicillinase-resistant penicillin (such as <a class="drug drug_general" data-topicid="9349" href="/z/d/drug information/9349.html" rel="external">dicloxacillin</a>). We use <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> if the patient is allergic to penicillin  (<a class="graphic graphic_table graphicRef67277" href="/z/d/graphic/67277.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gram-negative organism</strong> – <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">Ciprofloxacin</a>  (<a class="graphic graphic_table graphicRef67277" href="/z/d/graphic/67277.html" rel="external">table 1</a>). If the patient cannot take ciprofloxacin, we use intraperitoneal <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a>. Ceftazidime may be given continuously (500 mg/L loading dose followed by 125 mg/L in all subsequent exchanges) or intermittently (1000 to 1500 mg in one exchange daily). For intermittent dosing of intraperitoneal antibiotics, the dwell time should be at least six hours to allow adequate absorption [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gram stain results unavailable or inconclusive</strong> – Both a first-generation oral cephalosporin or a penicillinase-resistant penicillin and <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a>  (<a class="graphic graphic_table graphicRef67277" href="/z/d/graphic/67277.html" rel="external">table 1</a>). We use <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> if the patient is allergic to penicillin  (<a class="graphic graphic_table graphicRef67277" href="/z/d/graphic/67277.html" rel="external">table 1</a>). If the patient cannot take ciprofloxacin, we use intraperitoneal <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a> as described above for gram-negative organisms [<a href="#rid1">1</a>].</p><p></p><p>There are two exceptions to the approach defined above.</p><p class="bulletIndent1"><span class="glyph">●</span>The patient who has had prior infection or colonization with methicillin-resistant <em>S. aureus</em> (MRSA) and Gram stain showing gram-positive organisms should receive empiric treatment for MRSA. We use oral <a class="drug drug_general" data-topicid="9231" href="/z/d/drug information/9231.html" rel="external">cephalexin</a> or <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a> for broad-spectrum coverage and also give intraperitoneal <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> (15 to 30 mg/kg every five to seven days) to cover possible MRSA. Serum vancomycin levels should be checked prior to redosing to assure that a therapeutic level (goal 15 to 20 microgram/mL) is achieved, particularly among patients with residual kidney function, who may require a higher maintenance dose or more frequent dosing. For intermittent dosing of intraperitoneal antibiotics, the dwell time should be at least six hours to allow adequate absorption [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The patient who has had prior infection or colonization with <em>Pseudomonas</em> and Gram stain showing gram-negative organisms should receive an antipseudomonal antibiotic. We usually use <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a> monotherapy, as we do for all gram-negative organisms, but we treat for three weeks rather than two weeks, which is standard duration for other organisms [<a href="#rid56">56</a>]. If the patient cannot take ciprofloxacin, we use intraperitoneal <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a> as described above for gram-negative organisms [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1">Some clinicians treat potential <em>Pseudomonas</em> infections with two-drug therapy such as oral <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a> and with an intraperitoneal aminoglycoside (preferably <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">amikacin</a> [2 mg/kg in one exchange per day] or <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">tobramycin</a> [0.6 mg/kg in one exchange per day]) or intraperitoneal <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a> (using dose defined above). Continuous dosing (ie, adding antibiotic to each exchange) is not recommended for aminoglycosides. <em>Pseudomonas</em> infections are more likely to be associated with the development of antibiotic resistance with monotherapy [<a href="#rid1">1</a>].</p><p></p><p>Occasionally, empiric therapy may need to be based on local patterns of infection and trends in antibiotic resistance, although generally this does not overly influence the choice of initial antibiotic [<a href="#rid6">6</a>]. <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">Vancomycin</a> should not be used in routine therapy, since there is a high incidence of vancomycin-resistant organisms.</p><p class="headingAnchor" id="H2488584740"><span class="h2">Treatment duration and follow-up</span><span class="headingEndMark"> — </span>Antibiotic therapy is adjusted depending on culture and sensitivity results. In addition, we re-evaluate clinically after one week.</p><p>If the patient is improving, we continue antibiotics until the infection is completely resolved and for a <strong>minimum</strong> of two weeks for all organisms except <em>Pseudomonas</em>. If the patient has a <em>Pseudomonas</em> infection, we treat for a minimum of three weeks.</p><p>If the patient is not improving at the one-week evaluation, our approach depends on the culture and sensitivity results. If the organism is a <em>Staphylococcus</em> species and there is no improvement after one week, then oral <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> should be added to the regimen. Rifampin has good tissue penetration and acts synergistically with antistaphylococcal penicillins and <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>. Rifampin should not be given as single-agent therapy  (<a class="graphic graphic_table graphicRef67277" href="/z/d/graphic/67277.html" rel="external">table 1</a>) [<a href="#rid57">57,58</a>].</p><p>If the organism is a <em>Pseudomonas</em> species and the patient has not responded by one week, a second antipseudomonal drug, such as intraperitoneal <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a> (dosed continuously [500 mg/L loading dose followed by 125 mg/L in all subsequent exchanges] or intermittently [1000 to 1500 mg in one exchange daily]) or intraperitoneal aminoglycoside (such as <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">amikacin</a>, 2 mg/kg in one exchange per day, or <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">tobramycin</a>, 0.6 mg/kg in one exchange per day). Intraperitoneal aminoglycosides should be given intermittently rather than continuously. For intermittent dosing of intraperitoneal antibiotics, the dwell time should be at least six hours to allow adequate absorption [<a href="#rid1">1</a>].</p><p>Other antipseudomonal drugs, such as <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a>, <a class="drug drug_general" data-topicid="9775" href="/z/d/drug information/9775.html" rel="external">piperacillin</a>, <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">imipenem</a>, or <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a>, may also be used with <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a> [<a href="#rid56">56-58</a>].</p><p>For all other organisms, we rely on the sensitivities to direct antibiotics. The culture may be repeated at this point if initial results are considered unreliable. In addition, assess compliance with the regimen.</p><p>If appropriate antibiotic therapy has no effect on the infection after two weeks, the exit-site/tunnel infection is considered resistant. Surgical interventions are often indicated at this point [<a href="#rid58">58</a>]. (See <a class="local">'Resistant infection'</a> below.)</p><p>However, if at least some improvement is observed, we will continue antibiotic treatment for up to six weeks before surgical intervention. Patients who receive prolonged antibiotics should also receive antifungal prophylaxis. (See <a class="local">'Antifungal prophylaxis'</a> below.)</p><p class="headingAnchor" id="H3488503768"><span class="h3">Fungal infections</span><span class="headingEndMark"> — </span>Fungal infections are a rare cause of ESI, and there are little published data to direct treatment. It is important to ascertain that the fungus identified in the culture is not a contaminant. Repeat culture or demonstrating the absence of other micro-organisms will help to confirm this. The catheter should usually be <strong>removed</strong> if there is definite fungal ESI to prevent progression to fungal peritonitis. (See <a class="local">'Catheter removal and replacement'</a> below.)</p><p class="headingAnchor" id="H2578623900"><span class="h2">Antifungal prophylaxis</span><span class="headingEndMark"> — </span>Our approach towards antifungal prophylaxis, choice of agent, and dosing among patients on peritoneal dialysis are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1982.html" rel="external">"Fungal peritonitis in peritoneal dialysis", section on 'Prevention'</a> and  <a class="medical medical_review" href="/z/d/html/1882.html" rel="external">"Microbiology and therapy of peritonitis in peritoneal dialysis", section on 'Role of antifungal prophylaxis'</a>.)</p><p class="headingAnchor" id="H19"><span class="h2">Resistant infection</span><span class="headingEndMark"> — </span>Resistant infection is defined by persistent clinical findings despite optimal antibiotics. For all patients with resistant infection, we make certain that they are adherent to the therapeutic regimen, and also perform an ultrasound to help identify a fluid collection in the tunnel. For patients whose external cuff is not exposed and there is no evidence of abscess or tunnel infection, we treat with another week of antibiotic therapy. For patients whose external cuff is exposed, or if a fluid collection is observed, we refer them to a qualified clinician (eg, surgeon) to remove the external cuff of the catheter. Alternatively, these patients who have the cuff exposed can undergo simultaneous catheter removal and replacement. For patients whose peritoneal catheter or tunnel infection is due to a fungus, we refer them directly for catheter removal. (See <a class="local">'Catheter removal and replacement'</a> below.)</p><p>A thorough repeat examination should be performed for all patients with a resistant infection. We also perform an ultrasound to help identify a fluid collection in the tunnel [<a href="#rid63">63</a>]. When obtaining an ultrasound, it is important to specify that the catheter tract is the suspected site of infection so that the ultrasound gain is adjusted accordingly. In one study, ultrasonography revealed findings suggestive of abnormal fluid collections in 21 of 22 cases of ESI with tunnel infection (but also in 4 of 20 controls without an ESI) [<a href="#rid59">59</a>]. Computed tomography (CT) scanning or gallium scanning may be alternatives to ultrasound.</p><p>Movement of the exposed cuff in and out of the exit site may cause local trauma, thereby disrupting healthy granulation tissue and causing persistent infection. In addition, bacteria may be adherent to the cuff, resulting in resistance to antibiotics. Thus, if the external cuff is exposed, or if a fluid collection is observed, we remove the external cuff of the catheter to improve drainage. If the external cuff is not exposed and there is no evidence of abscess or tunnel infection, then another week of therapy may be helpful. </p><p>Removal of the external cuff is typically performed under sterile conditions and local anesthesia either at the patient's bedside or in an outpatient office [<a href="#rid64">64</a>]. The techniques used vary depending upon the clinician's preference and experience. As examples, cuffs can be teased away from the catheter using blunt forceps [<a href="#rid65">65</a>]. Another method of cuff removal is called "cuff shaving." While some clinicians use scalpels for cuff shaving, others prefer to use abrasives such as sandpaper, emery boards, or bovine scrapers to remove the cuff, which have a much lower risk of damage to the catheter compared with scalpels. Because cuff shaving can damage the catheter, it needs to be performed by a clinician experienced with the technique [<a href="#rid66">66</a>]. If the cuff is only partially exposed, the tunnel may need to be deroofed for complete exposure and removal. </p><p>Conflicting results have been observed with the cuff-shaving procedure [<a href="#rid2">2,65,67-69</a>]. In some studies, cuff shaving was effective for resistant ESIs [<a href="#rid66">66,68,69</a>]. In one study, for example, 48 patients underwent 53 cuff-shaving procedures [<a href="#rid66">66</a>]. Among these patients, 34 percent of the infections were due to <em>S. aureus</em>, 17 percent due to <em>Corynebacterium </em>spp, 15 percent due to <em>P. aeruginosa</em>, and 8 percent due to fungal agents. Cuff shaving was associated with resolution of 39 of the 53 infections (74 percent), with the remaining patients requiring catheter removal due to persistent infection or leak. </p><p>After a total of three weeks of antibiotics, if there is still no improvement, the patient should have the catheter removed. (See <a class="local">'Catheter removal and replacement'</a> below.)</p><p>An alternative to cuff shaving is relocation of the exit site with removal of the external cuff, which can also be performed as a day procedure under local anesthesia. One retrospective study from the United Kingdom analyzed outcomes of 27 patients with a resistant ESI (mostly <em>Pseudomonas </em>and <em>S. aureus </em>infections) who were treated with exit-site relocation and cuff removal [<a href="#rid70">70</a>]. Patients were permitted to resume peritoneal dialysis immediately following the procedure, and oral antibiotics were continued for two to four weeks until healthy granulation tissue was observed. At a follow-up of four years (range 11 to 79 months), most patients (74 percent) had long-term resolution of infection; seven required catheter removal due to recurrent ESI (n = 5) or tunnel infection (n = 2). While these findings are encouraging, the independent benefit of the procedure is difficult to assess given the lack of a control group and the administration of cointerventions, including cuff removal and additional antibiotic therapy. </p><p>Other observational studies have also found benefit with relocation of the exit site. In one study of 52 patients with intractable exit-site or tunnel infections who underwent cuff shaving and creation of a new tunnel, infection-free catheter survival at 6 and 12 months was 57 and 35 percent, respectively [<a href="#rid71">71</a>]. Another study that evaluated 40 catheter diversion procedures among 33 patients with exit-site or tunnel infection found the infection-free rate was 90 percent at 30 days and 67 percent at 90 days [<a href="#rid72">72</a>]. Importantly, the median peritoneal dialysis catheter survival was 84 months, and patients undergoing catheter diversion had longer catheter survival and were more likely to stay on peritoneal dialysis than patients who had their catheters removed and replaced.</p><p class="headingAnchor" id="H20"><span class="h2">Catheter removal and replacement</span><span class="headingEndMark"> — </span>Catheter removal is required for some exit-site and tunnel infections. The following are indications for catheter removal [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Exit-site or tunnel infection occurring simultaneously with or progressing to peritonitis during antibiotic treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The exit-site or tunnel infection is resistant to antibiotics. A resistant infection is defined as one that shows no improvement after three weeks of appropriate antibiotics with/or without cuff shaving or has not completely resolved after six weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The exit-site or tunnel infection is caused by fungus. (See <a class="local">'Fungal infections'</a> above.)</p><p></p><p>In all cases, perioperative antibiotics should be given [<a href="#rid57">57</a>] and then continued for one to two weeks after catheter removal.</p><p>The catheter should be removed by surgical dissection rather than by traction. Removal by traction may result in retention of the peritoneal and/or subcutaneous cuffs, which could lead to local infection or sepsis. In one study, a change in removal practice from traction to surgical dissection resulted in a significant reduction in the incidence of local infections (0 versus 24 percent) [<a href="#rid73">73</a>].</p><p>If there is no peritonitis associated with the ESI, the infected catheter can be removed and a new catheter placed simultaneously in the opposite lower quadrant [<a href="#rid74">74</a>]. The "clean" step of inserting the new catheter on the opposite side of the abdomen is performed before the "dirty" step of removing the old catheter, with care to avoid cross-contamination of wounds. This procedure is commonly performed in the pediatric population and has also been shown to be effective in adults [<a href="#rid75">75,76</a>]. In one study, simultaneous catheter placement and removal was successful in 30 of 36 patients [<a href="#rid75">75</a>]. In the remaining six, persistent infection developed in two, and the procedure was not successful for technical reasons in four.</p><p>A new catheter should <strong>not</strong> be placed at the time the infected catheter is removed if active peritonitis is present. We wait at least two weeks after catheter removal and complete resolution of peritoneal symptoms before placing a new catheter. This practice is consistent with the 2017 update of the ISPD catheter-related infection recommendations [<a href="#rid1">1</a>]. However, simultaneous catheter removal and replacement can be performed for relapsing peritonitis caused by the <em>Staphylococcus</em> species if antibiotic therapy resolves abdominal symptoms and the peritoneal fluid cell count is &lt;100/microL. This practice is consistent with the 2019 ISPD guidelines on creating and maintaining the peritoneal dialysis catheter [<a href="#rid77">77</a>]. (See  <a class="medical medical_review" href="/z/d/html/1882.html" rel="external">"Microbiology and therapy of peritonitis in peritoneal dialysis"</a>.)</p><p class="headingAnchor" id="H4036598391"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Most exit-site infections (ESIs) resolve with appropriate treatment. However, some infections do not resolve. Catheter infections with <em>Pseudomonas</em> are particularly problematic, with lack of response to treatment in approximately 50 percent of cases [<a href="#rid60">60</a>]. In a series of 14 patients with <em>Pseudomonas</em> ESI treated with oral and intraperitoneal antibiotics, only six patients had a cure with no recurrence [<a href="#rid78">78</a>].</p><p>If the ESI is not treated or does not respond to treatment, two major complications may result, including peritonitis and removal of the catheter.</p><p>Peritonitis is the most serious complication [<a href="#rid62">62</a>]. Patients who develop an ESI are much more likely to develop peritonitis, even if the ESI was appropriately treated [<a href="#rid79">79</a>].</p><p>Peritonitis most commonly results from <em>S. aureus</em> or <em>P. aeruginosa</em>-related ESIs with tunnel infections. In the study cited above, among 14 patients with <em>Pseudomonas</em> ESI, two patients had <em>Pseudomonas</em> peritonitis at presentation, and four developed <em>Pseudomonas</em> peritonitis [<a href="#rid78">78</a>].</p><p>Resistant ESIs may also result in removal of the catheter, requiring the temporary or permanent switch from peritoneal dialysis to hemodialysis [<a href="#rid62">62</a>]. In the study above, of 14 patients, the catheter was removed in four patients because of peritonitis and in three patients because of the severity or recurrence of the ESI [<a href="#rid78">78</a>]. (See  <a class="medical medical_review" href="/z/d/html/1882.html" rel="external">"Microbiology and therapy of peritonitis in peritoneal dialysis", section on 'Prognosis'</a>.)</p><p>ESIs are rarely a direct cause of mortality unless they are untreated and progress to bacterial or fungal peritonitis.</p><p class="headingAnchor" id="H12888872"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/4426.html" rel="external">"Patient education: Peritoneal dialysis (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H12691197"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microbiology </strong>– Peritoneal dialysis requires the placement and maintenance of a catheter in the peritoneal cavity. The exit site and catheter tunnel are prone to bacterial infection. More than 50 percent of infections are caused by gram-positive organisms, with <em>Pseudomonas aeruginosa</em> and <em>Escherichia coli</em> causing the majority of the remainder. (See <a class="local">'Introduction'</a> above and <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention </strong>– Exit-site and tunnel infections are decreased by preventive measures. In addition to washing the exit site daily, we recommend application of topical antibiotics versus no antibiotics (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). Multiple studies have shown that topical antibiotics reduce the risk of exit-site infections (ESIs). We use 0.1% topical <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> sulfate administered daily; <a class="drug drug_general" data-topicid="9668" href="/z/d/drug information/9668.html" rel="external">mupirocin</a> is also effective. (See <a class="local">'Antimicrobial prophylaxis'</a> above.)</p><p></p><p class="bulletIndent1">Preventive systemic antibiotics are also given prior to catheter placement and following any inadvertent trauma to the catheter. (See <a class="local">'Prior to catheter placement'</a> above and  <a class="medical medical_review" href="/z/d/html/1885.html" rel="external">"Placement of the peritoneal dialysis catheter"</a> and <a class="local">'Oral antibiotics following catheter trauma'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation and evaluation </strong>– The exit site should be examined daily by the patient and at least monthly by a clinician and whenever the patient detects a change in the appearance of the exit site. The clinical presentation of exit-site or tunnel infection is described above. (See <a class="local">'Clinical presentation and evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Empiric therapy </strong>– We treat all patients with exit-site and/or tunnel infections with systemic antibiotics. Antibiotics are effective in treating most ESIs. Our approach to patients is defined above. (See <a class="local">'Empiric therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Catheter removal and replacement </strong>– The catheter should be removed if the exit-site or tunnel infection occurs simultaneously with or progresses to peritonitis. Catheter removal or exit-site diversion should be performed for exit-site or tunnel infection that shows no improvement after three weeks of appropriate antibiotics with or without cuff shaving, or the exit-site or tunnel infection is caused by fungus. (See <a class="local">'Catheter removal and replacement'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Szeto CC, Li PK, Johnson DW, et al. ISPD Catheter-Related Infection Recommendations: 2017 Update. Perit Dial Int 2017; 37:141.</a></li><li><a class="nounderline abstract_t">Scalamogna A, Castelnovo C, De Vecchi A, Ponticelli C. Exit-site and tunnel infections in continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis 1991; 18:674.</a></li><li><a class="nounderline abstract_t">Nessim SJ, Komenda P, Rigatto C, et al. Frequency and microbiology of peritonitis and exit-site infection among obese peritoneal dialysis patients. Perit Dial Int 2013; 33:167.</a></li><li><a class="nounderline abstract_t">Tse KC, Lui SL, Cheng VC, et al. A cluster of rapidly growing mycobacterial peritoneal dialysis catheter exit-site infections. Am J Kidney Dis 2007; 50:e1.</a></li><li><a class="nounderline abstract_t">Schiffl H, Mücke C, Lang SM. Exit-site infections by non-diphtheria corynebacteria in CAPD. Perit Dial Int 2004; 24:454.</a></li><li><a class="nounderline abstract_t">Bernardini J, Bender F, Florio T, et al. Randomized, double-blind trial of antibiotic exit site cream for prevention of exit site infection in peritoneal dialysis patients. J Am Soc Nephrol 2005; 16:539.</a></li><li><a class="nounderline abstract_t">McQuillan RF, Chiu E, Nessim S, et al. A randomized controlled trial comparing mupirocin and polysporin triple ointments in peritoneal dialysis patients: the MP3 Study. Clin J Am Soc Nephrol 2012; 7:297.</a></li><li><a class="nounderline abstract_t">Xu G, Tu W, Xu C. Mupirocin for preventing exit-site infection and peritonitis in patients undergoing peritoneal dialysis. Nephrol Dial Transplant 2010; 25:587.</a></li><li><a class="nounderline abstract_t">Gloor HJ, Nichols WK, Sorkin MI, et al. Peritoneal access and related complications in continuous ambulatory peritoneal dialysis. Am J Med 1983; 74:593.</a></li><li><a class="nounderline abstract_t">Vogt K, Binswanger U, Buchmann P, et al. Catheter-related complications during continuous ambulatory peritoneal dialysis (CAPD): a retrospective study on sixty-two double-cuff Tenckhoff catheters. Am J Kidney Dis 1987; 10:47.</a></li><li><a class="nounderline abstract_t">Chen SS, Sheth H, Piraino B, Bender F. Long-Term Exit-Site Gentamicin Prophylaxis and Gentamicin Resistance in a Peritoneal Dialysis Program. Perit Dial Int 2016; 36:387.</a></li><li><a class="nounderline abstract_t">Lin J, Ye H, Li J, et al. Prevalence and risk factors of exit-site infection in incident peritoneal dialysis patients. Perit Dial Int 2020; 40:164.</a></li><li><a class="nounderline abstract_t">Lee A. Swimming on Peritoneal Dialysis: Recommendations from Australian PD Units. Perit Dial Int 2019; 39:527.</a></li><li><a class="nounderline abstract_t">Tanabe K, Okamoto S, Hiramatsu Asano S, Wada J. Capnocytophaga canimorsus peritonitis diagnosed by mass spectrometry in a diabetic patient undergoing peritoneal dialysis: a case report. BMC Nephrol 2019; 20:219.</a></li><li><a class="nounderline abstract_t">Abraham G, Savin E, Ayiomamitis, et al. Natural history of exit site infection (ESI) in patients on continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Int 1988; 8:211.</a></li><li><a class="nounderline abstract_t">Gleeson S, Mulroy E, Bryce E, et al. Burkholderia cepacia: An Outbreak in the Peritoneal Dialysis Unit. Perit Dial Int 2019; 39:92.</a></li><li><a class="nounderline abstract_t">Lobbedez T, Gardam M, Dedier H, et al. Routine use of mupirocin at the peritoneal catheter exit site and mupirocin resistance: still low after 7 years. Nephrol Dial Transplant 2004; 19:3140.</a></li><li><a class="nounderline abstract_t">O'Seaghdha CM, Foley RN. Septicemia, access, cardiovascular disease, and death in dialysis patients. Perit Dial Int 2005; 25:534.</a></li><li><a class="nounderline abstract_t">Li PK, Chow KM, Cho Y, et al. ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Perit Dial Int 2022; 42:110.</a></li><li><a class="nounderline abstract_t">Nasal mupirocin prevents Staphylococcus aureus exit-site infection during peritoneal dialysis. Mupirocin Study Group. J Am Soc Nephrol 1996; 7:2403.</a></li><li><a class="nounderline abstract_t">Santos C, Pérez-Fontán M, Rodríguez-Carmona A, et al. Identification of Targets for Prevention of Peritoneal Catheter Tunnel and Exit-Site Infections in Low Incidence Settings. Perit Dial Int 2016; 36:43.</a></li><li><a class="nounderline abstract_t">Luzar MA, Brown CB, Balf D, et al. Exit-site care and exit-site infection in continuous ambulatory peritoneal dialysis (CAPD): results of a randomized multicenter trial. Perit Dial Int 1990; 10:25.</a></li><li><a class="nounderline abstract_t">Waite NM, Webster N, Laurel M, et al. The efficacy of exit site povidone-iodine ointment in the prevention of early peritoneal dialysis-related infections. Am J Kidney Dis 1997; 29:763.</a></li><li><a class="nounderline abstract_t">Mushahar L, Mei LW, Yusuf WS, et al. Exit-Site Dressing and Infection in Peritoneal Dialysis: A Randomized Controlled Pilot Trial. Perit Dial Int 2016; 36:135.</a></li><li><a class="nounderline abstract_t">Thodis E, Bhaskaran S, Pasadakis P, et al. Decrease in Staphylococcus aureus exit-site infections and peritonitis in CAPD patients by local application of mupirocin ointment at the catheter exit site. Perit Dial Int 1998; 18:261.</a></li><li><a class="nounderline abstract_t">Casey M, Taylor J, Clinard P, et al. Application of mupirocin cream at the catheter exit site reduces exit-site infections and peritonitis in peritoneal dialysis patients. Perit Dial Int 2000; 20:566.</a></li><li><a class="nounderline abstract_t">Ritzau J, Hoffman RM, Tzamaloukas AH. Effect of preventing Staphylococcus aureus carriage on rates of peritoneal catheter-related staphylococcal infections. Literature synthesis. Perit Dial Int 2001; 21:471.</a></li><li><a class="nounderline abstract_t">Piraino B, Bernardini J, Florio T, Fried L. Staphylococcus aureus prophylaxis and trends in gram-negative infections in peritoneal dialysis patients. Perit Dial Int 2003; 23:456.</a></li><li><a class="nounderline abstract_t">Conly JM, Vas S. Increasing mupirocin resistance of Staphylococcus aureus in CAPD--should it continue to be used as prophylaxis? Perit Dial Int 2002; 22:649.</a></li><li><a class="nounderline abstract_t">Bernardini J, Piraino B, Holley J, et al. A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin. Am J Kidney Dis 1996; 27:695.</a></li><li><a class="nounderline abstract_t">Lim CT, Wong KS, Foo MW. The impact of topical mupirocin on peritoneal dialysis infection rates in Singapore General Hospital. Nephrol Dial Transplant 2005; 20:1702.</a></li><li><a class="nounderline abstract_t">Pérez-Fontán M, Rosales M, Rodríguez-Carmona A, et al. Mupirocin resistance after long-term use for Staphylococcus aureus colonization in patients undergoing chronic peritoneal dialysis. Am J Kidney Dis 2002; 39:337.</a></li><li><a class="nounderline abstract_t">Annigeri R, Conly J, Vas S, et al. Emergence of mupirocin-resistant Staphylococcus aureus in chronic peritoneal dialysis patients using mupirocin prophylaxis to prevent exit-site infection. Perit Dial Int 2001; 21:554.</a></li><li><a class="nounderline abstract_t">Al-Hwiesh AK, Abdul-Rahman IS, Al-Muhanna FA, et al. Prevention of peritoneal dialysis catheter infections in Saudi peritoneal dialysis patients: the emergence of high-level mupirocin resistance. Int J Artif Organs 2013; 36:473.</a></li><li><a class="nounderline abstract_t">Chu KH, Choy WY, Cheung CC, et al. A prospective study of the efficacy of local application of gentamicin versus mupirocin in the prevention of peritoneal dialysis catheter-related infections. Perit Dial Int 2008; 28:505.</a></li><li><a class="nounderline abstract_t">Mahaldar A, Weisz M, Kathuria P. Comparison of gentamicin and mupirocin in the prevention of exit-site infection and peritonitis in peritoneal dialysis. Adv Perit Dial 2009; 25:56.</a></li><li><a class="nounderline abstract_t">Tsai CC, Yang PS, Liu CL, et al. Comparison of topical mupirocin and gentamicin in the prevention of peritoneal dialysis-related infections: A systematic review and meta-analysis. Am J Surg 2018; 215:179.</a></li><li><a class="nounderline abstract_t">Chua AN, Goldstein SL, Bell D, Brewer ED. Topical mupirocin/sodium hypochlorite reduces peritonitis and exit-site infection rates in children. Clin J Am Soc Nephrol 2009; 4:1939.</a></li><li><a class="nounderline abstract_t">Montenegro J, Saracho R, Aguirre R, et al. Exit-site care with ciprofloxacin otologic solution prevents polyurethane catheter infection in peritoneal dialysis patients. Perit Dial Int 2000; 20:209.</a></li><li><a class="nounderline abstract_t">Danguilan RA, Evangelista LP, Abrenica MS, Rondilla SM. Comparative study of mupirocin and sodium fucidate in the prophylaxis of exit-site infections in CAPD patients. Perit Dial Int 2003; 23:593.</a></li><li><a class="nounderline abstract_t">Pommer W, Brauner M, Westphale HJ, et al. Effect of a silver device in preventing catheter-related infections in peritoneal dialysis patients: silver ring prophylaxis at the catheter exit study. Am J Kidney Dis 1998; 32:752.</a></li><li><a class="nounderline abstract_t">Crabtree JH, Burchette RJ, Siddiqi RA, et al. The efficacy of silver-ion implanted catheters in reducing peritoneal dialysis-related infections. Perit Dial Int 2003; 23:368.</a></li><li class="breakAll">Castro Notario MJ. Cuidados del orificio de salida del cater peritoneal. In: Manual Practico de Dialisis Peritoneal, Coronel F, Montenegro J, Selgas R, et al (Eds), Atrium Communicacion Estrategica, Barcelona, Spin 2005. p.293.</li><li><a class="nounderline abstract_t">Núñez-Moral M, Sánchez-Álvarez E, González-Díaz I, et al. Exit-site infection of peritoneal catheter is reduced by the use of polyhexanide. results of a prospective randomized trial. Perit Dial Int 2014; 34:271.</a></li><li><a class="nounderline abstract_t">Findlay A, Serrano C, Punzalan S, Fan SL. Increased peritoneal dialysis exit site infections using topical antiseptic polyhexamethylene biguanide compared to mupirocin: results of a safety interim analysis of an open-label prospective randomized study. Antimicrob Agents Chemother 2013; 57:2026.</a></li><li><a class="nounderline abstract_t">Zimmerman SW, Ahrens E, Johnson CA, et al. Randomized controlled trial of prophylactic rifampin for peritoneal dialysis-related infections. Am J Kidney Dis 1991; 18:225.</a></li><li><a class="nounderline abstract_t">Falagas ME, Fragoulis KN, Bliziotis IA. Oral rifampin for prevention of S. aureus carriage-related infections in patients with renal failure--a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 2006; 21:2536.</a></li><li><a class="nounderline abstract_t">Johnson DW, Clark C, Isbel NM, et al. The honeypot study protocol: a randomized controlled trial of exit-site application of medihoney antibacterial wound gel for the prevention of catheter-associated infections in peritoneal dialysis patients. Perit Dial Int 2009; 29:303.</a></li><li><a class="nounderline abstract_t">Johnson DW, van Eps C, Mudge DW, et al. Randomized, controlled trial of topical exit-site application of honey (Medihoney) versus mupirocin for the prevention of catheter-associated infections in hemodialysis patients. J Am Soc Nephrol 2005; 16:1456.</a></li><li><a class="nounderline abstract_t">Pérez-Fontán M, Rosales M, Rodríguez-Carmona A, et al. Treatment of Staphylococcus aureus nasal carriers in CAPD with mupirocin. Adv Perit Dial 1992; 8:242.</a></li><li><a class="nounderline abstract_t">Strippoli GF, Tong A, Johnson D, et al. Antimicrobial agents to prevent peritonitis in peritoneal dialysis: a systematic review of randomized controlled trials. Am J Kidney Dis 2004; 44:591.</a></li><li><a class="nounderline abstract_t">Hui YH, So WK, Ng MS, et al. Treating peritoneal dialysis catheter exit-site granulomas with chlorhexidine swabstick: A pilot study. J Ren Care 2021; 47:103.</a></li><li><a class="nounderline abstract_t">Huang WH, Yen TH, Chan MJ, Su YJ. Impact of environmental particulate matter and peritoneal dialysis-related infection in patients undergoing peritoneal dialysis. Medicine (Baltimore) 2014; 93:e149.</a></li><li><a class="nounderline abstract_t">Bennett PN, Bohm C, Harasemiw O, et al. Physical activity and exercise in peritoneal dialysis: International Society for Peritoneal Dialysis and the Global Renal Exercise Network practice recommendations. Perit Dial Int 2022; 42:8.</a></li><li><a class="nounderline abstract_t">Broughton A, Verger C, Goffin E. Pets-related peritonitis in peritoneal dialysis: companion animals or trojan horses? Semin Dial 2010; 23:306.</a></li><li><a class="nounderline abstract_t">Keane WF, Bailie GR, Boeschoten E, et al. Adult peritoneal dialysis-related peritonitis treatment recommendations: 2000 update. Perit Dial Int 2000; 20:396.</a></li><li><a class="nounderline abstract_t">Piraino B, Bailie GR, Bernardini J, et al. Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int 2005; 25:107.</a></li><li><a class="nounderline abstract_t">Li PK, Szeto CC, Piraino B, et al. Peritoneal dialysis-related infections recommendations: 2010 update. Perit Dial Int 2010; 30:393.</a></li><li><a class="nounderline abstract_t">Kwan TH, Tong MK, Siu YP, et al. Ultrasonography in the management of exit site infections in peritoneal dialysis patients. Nephrology (Carlton) 2004; 9:348.</a></li><li><a class="nounderline abstract_t">Teitelbaum I, Burkart J. Peritoneal dialysis. Am J Kidney Dis 2003; 42:1082.</a></li><li><a class="nounderline abstract_t">Gonthier D, Bernardini J, Holley JL, Piraino B. Erythema: does it indicate infection in a peritoneal catheter exit site? Adv Perit Dial 1992; 8:230.</a></li><li><a class="nounderline abstract_t">Piraino B, Bernardini J, Sorkin M. Catheter infections as a factor in the transfer of continuous ambulatory peritoneal dialysis patients to hemodialysis. Am J Kidney Dis 1989; 13:365.</a></li><li><a class="nounderline abstract_t">Vychytil A, Lilaj T, Lorenz M, et al. Ultrasonography of the catheter tunnel in peritoneal dialysis patients: what are the indications? Am J Kidney Dis 1999; 33:722.</a></li><li><a class="nounderline abstract_t">Terawaki H, Nakano H, Ogura M, et al. Unroofing surgery with en bloc resection of the skin and tissues around the peripheral cuff. Perit Dial Int 2013; 33:573.</a></li><li><a class="nounderline abstract_t">Debowski JA, Wærp C, Kjellevold SA, Abedini S. Cuff extrusion in peritoneal dialysis: single-centre experience with the cuff-shaving procedure in five patients over a 4-year period. Clin Kidney J 2017; 10:131.</a></li><li><a class="nounderline abstract_t">Meng C, Beco A, Oliveira A, et al. Peritoneal Dialysis Cuff-Shaving-A Salvage Therapy for Refractory Exit-Site Infections. Perit Dial Int 2019; 39:276.</a></li><li><a class="nounderline abstract_t">Piraino B, Bernardini J, Pietzman A, Sorkin M. Failure of peritoneal catheter cuff shaving to eradicate infection. Perit Dial Bull 1987; 7:179.</a></li><li><a class="nounderline abstract_t">Scalamogna A, De Vecchi A, Maccario M, et al. Cuff-shaving procedure. A rescue treatment for exit-site infection unresponsive to medical therapy. Nephrol Dial Transplant 1995; 10:2325.</a></li><li><a class="nounderline abstract_t">Suh H, Wadhwa NK, Cabralda T, et al. Persistent exit-site/tunnel infection and subcutaneous cuff removal in PD patients. Adv Perit Dial 1997; 13:233.</a></li><li><a class="nounderline abstract_t">Kirmizis D, Bowes E, Ansari B, Cairns H. Exit-Site Relocation: A Novel, Straightforward Technique for Exit-Site Infections. Perit Dial Int 2019; 39:350.</a></li><li><a class="nounderline abstract_t">Kang SH, Cho KH, Kim AY, Do JY. Catheter salvage using revision for a peritoneal dialysis catheter with intractable exit site and/or tunnel infections. Semin Dial 2023; 36:53.</a></li><li><a class="nounderline abstract_t">Oki R, Hamasaki Y, Komaru Y, et al. Catheter Diversion Procedure With Exit-Site Renewal Promotes Peritoneal Dialysis Catheter Survival. Kidney Int Rep 2021; 6:325.</a></li><li><a class="nounderline abstract_t">Elkabir JJ, Riaz AA, Agarwal SK, Williams G. Delayed complications following Tenckhoff catheter removal. Nephrol Dial Transplant 1999; 14:1550.</a></li><li><a class="nounderline abstract_t">Singhal MK, Vas SI, Oreopoulos DG. Treatment of peritoneal dialysis catheter-related infections by simultaneous catheter removal and replacement. Is it safe? Perit Dial Int 1998; 18:565.</a></li><li><a class="nounderline abstract_t">Swartz R, Messana J, Reynolds J, Ranjit U. Simultaneous catheter replacement and removal in refractory peritoneal dialysis infections. Kidney Int 1991; 40:1160.</a></li><li><a class="nounderline abstract_t">Lui SL, Yip T, Tse KC, et al. Treatment of refractory pseudomonas aeruginosa exit-site infection by simultaneous removal and reinsertion of peritoneal dialysis catheter. Perit Dial Int 2005; 25:560.</a></li><li><a class="nounderline abstract_t">Crabtree JH, Shrestha BM, Chow KM, et al. Creating and Maintaining Optimal Peritoneal Dialysis Access in the Adult Patient: 2019 Update. Perit Dial Int 2019; 39:414.</a></li><li><a class="nounderline abstract_t">Burkhalter F, Clemenger M, Haddoub SS, et al. Pseudomonas exit-site infection: treatment outcomes with topical gentamicin in addition to systemic antibiotics. Clin Kidney J 2015; 8:781.</a></li><li><a class="nounderline abstract_t">Kazmi HR, Raffone FD, Kliger AS, Finkelstein FO. Pseudomonas exit site infections in continuous ambulatory peritoneal dialysis patients. J Am Soc Nephrol 1992; 2:1498.</a></li></ol></div><div id="topicVersionRevision">Topic 1888 Version 38.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28360365" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : ISPD Catheter-Related Infection Recommendations: 2017 Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1962652" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Exit-site and tunnel infections in continuous ambulatory peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22942268" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Frequency and microbiology of peritonitis and exit-site infection among obese peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17591517" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A cluster of rapidly growing mycobacterial peritoneal dialysis catheter exit-site infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15490985" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Exit-site infections by non-diphtheria corynebacteria in CAPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15625071" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Randomized, double-blind trial of antibiotic exit site cream for prevention of exit site infection in peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22134627" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A randomized controlled trial comparing mupirocin and polysporin triple ointments in peritoneal dialysis patients: the MP3 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19679557" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Mupirocin for preventing exit-site infection and peritonitis in patients undergoing peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6837587" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Peritoneal access and related complications in continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3605083" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Catheter-related complications during continuous ambulatory peritoneal dialysis (CAPD): a retrospective study on sixty-two double-cuff Tenckhoff catheters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26634567" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Long-Term Exit-Site Gentamicin Prophylaxis and Gentamicin Resistance in a Peritoneal Dialysis Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32072873" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Prevalence and risk factors of exit-site infection in incident peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31582469" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Swimming on Peritoneal Dialysis: Recommendations from Australian PD Units.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31200664" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Capnocytophaga canimorsus peritonitis diagnosed by mass spectrometry in a diabetic patient undergoing peritoneal dialysis: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Natural history of exit site infection (ESI) in patients on continuous ambulatory peritoneal dialysis (CAPD)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30692235" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Burkholderia cepacia: An Outbreak in the Peritoneal Dialysis Unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15466881" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Routine use of mupirocin at the peritoneal catheter exit site and mupirocin resistance: still low after 7 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16411515" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Septicemia, access, cardiovascular disease, and death in dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35264029" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8959632" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Nasal mupirocin prevents Staphylococcus aureus exit-site infection during peritoneal dialysis. Mupirocin Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25292406" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Identification of Targets for Prevention of Peritoneal Catheter Tunnel and Exit-Site Infections in Low Incidence Settings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2085577" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Exit-site care and exit-site infection in continuous ambulatory peritoneal dialysis (CAPD): results of a randomized multicenter trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9159313" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The efficacy of exit site povidone-iodine ointment in the prevention of early peritoneal dialysis-related infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26374836" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Exit-Site Dressing and Infection in Peritoneal Dialysis: A Randomized Controlled Pilot Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9663889" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Decrease in Staphylococcus aureus exit-site infections and peritonitis in CAPD patients by local application of mupirocin ointment at the catheter exit site.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11117248" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Application of mupirocin cream at the catheter exit site reduces exit-site infections and peritonitis in peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11757831" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Effect of preventing Staphylococcus aureus carriage on rates of peritoneal catheter-related staphylococcal infections. Literature synthesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14604197" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Staphylococcus aureus prophylaxis and trends in gram-negative infections in peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12556065" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Increasing mupirocin resistance of Staphylococcus aureus in CAPD--should it continue to be used as prophylaxis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8629630" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15855200" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The impact of topical mupirocin on peritoneal dialysis infection rates in Singapore General Hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11840374" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Mupirocin resistance after long-term use for Staphylococcus aureus colonization in patients undergoing chronic peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11783763" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Emergence of mupirocin-resistant Staphylococcus aureus in chronic peritoneal dialysis patients using mupirocin prophylaxis to prevent exit-site infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23897229" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Prevention of peritoneal dialysis catheter infections in Saudi peritoneal dialysis patients: the emergence of high-level mupirocin resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18708544" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A prospective study of the efficacy of local application of gentamicin versus mupirocin in the prevention of peritoneal dialysis catheter-related infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19886318" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Comparison of gentamicin and mupirocin in the prevention of exit-site infection and peritonitis in peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28341139" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Comparison of topical mupirocin and gentamicin in the prevention of peritoneal dialysis-related infections: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19820132" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Topical mupirocin/sodium hypochlorite reduces peritonitis and exit-site infection rates in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10809245" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Exit-site care with ciprofloxacin otologic solution prevents polyurethane catheter infection in peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14703203" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Comparative study of mupirocin and sodium fucidate in the prophylaxis of exit-site infections in CAPD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9820444" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Effect of a silver device in preventing catheter-related infections in peritoneal dialysis patients: silver ring prophylaxis at the catheter exit study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12968845" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The efficacy of silver-ion implanted catheters in reducing peritoneal dialysis-related infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12968845" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The efficacy of silver-ion implanted catheters in reducing peritoneal dialysis-related infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24497599" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Exit-site infection of peritoneal catheter is reduced by the use of polyhexanide. results of a prospective randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23403425" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Increased peritoneal dialysis exit site infections using topical antiseptic polyhexamethylene biguanide compared to mupirocin: results of a safety interim analysis of an open-label prospective randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1867179" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Randomized controlled trial of prophylactic rifampin for peritoneal dialysis-related infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16705024" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Oral rifampin for prevention of S. aureus carriage-related infections in patients with renal failure--a meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19458303" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The honeypot study protocol: a randomized controlled trial of exit-site application of medihoney antibacterial wound gel for the prevention of catheter-associated infections in peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15788475" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Randomized, controlled trial of topical exit-site application of honey (Medihoney) versus mupirocin for the prevention of catheter-associated infections in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1361797" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Treatment of Staphylococcus aureus nasal carriers in CAPD with mupirocin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15384009" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Antimicrobial agents to prevent peritonitis in peritoneal dialysis: a systematic review of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33336530" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Treating peritoneal dialysis catheter exit-site granulomas with chlorhexidine swabstick: A pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25437027" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Impact of environmental particulate matter and peritoneal dialysis-related infection in patients undergoing peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34743628" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Physical activity and exercise in peritoneal dialysis: International Society for Peritoneal Dialysis and the Global Renal Exercise Network practice recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20636924" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Pets-related peritonitis in peritoneal dialysis: companion animals or trojan horses?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11007371" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Adult peritoneal dialysis-related peritonitis treatment recommendations: 2000 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15796137" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Peritoneal dialysis-related infections recommendations: 2005 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20628102" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Peritoneal dialysis-related infections recommendations: 2010 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15663635" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Ultrasonography in the management of exit site infections in peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14582053" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1361794" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Erythema: does it indicate infection in a peritoneal catheter exit site?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2719024" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Catheter infections as a factor in the transfer of continuous ambulatory peritoneal dialysis patients to hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10196015" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Ultrasonography of the catheter tunnel in peritoneal dialysis patients: what are the indications?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24133083" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Unroofing surgery with en bloc resection of the skin and tissues around the peripheral cuff.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28638613" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Cuff extrusion in peritoneal dialysis: single-centre experience with the cuff-shaving procedure in five patients over a 4-year period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30846605" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Peritoneal Dialysis Cuff-Shaving-A Salvage Therapy for Refractory Exit-Site Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Failure of peritoneal catheter cuff shaving to eradicate infection</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8808234" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Cuff-shaving procedure. A rescue treatment for exit-site infection unresponsive to medical therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9360689" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Persistent exit-site/tunnel infection and subcutaneous cuff removal in PD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31123073" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Exit-Site Relocation: A Novel, Straightforward Technique for Exit-Site Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35506330" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Catheter salvage using revision for a peritoneal dialysis catheter with intractable exit site and/or tunnel infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33615057" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Catheter Diversion Procedure With Exit-Site Renewal Promotes Peritoneal Dialysis Catheter Survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10383023" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Delayed complications following Tenckhoff catheter removal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9932653" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Treatment of peritoneal dialysis catheter-related infections by simultaneous catheter removal and replacement. Is it safe?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1762318" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Simultaneous catheter replacement and removal in refractory peritoneal dialysis infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16411522" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Treatment of refractory pseudomonas aeruginosa exit-site infection by simultaneous removal and reinsertion of peritoneal dialysis catheter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31028108" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Creating and Maintaining Optimal Peritoneal Dialysis Access in the Adult Patient: 2019 Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26613039" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Pseudomonas exit-site infection: treatment outcomes with topical gentamicin in addition to systemic antibiotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1600121" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Pseudomonas exit site infections in continuous ambulatory peritoneal dialysis patients.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
